earnings
confidence high
sentiment positive
materiality 0.80
Merck Q1 sales $15.9B (+50% YoY); Non-GAAP EPS $2.14; raises full-year guidance
Merck & Co., Inc.
2022-Q1 EPS reported
$1.70
revenue$15,901,000,000
- Sales $15.9B, +50% YoY (52% ex-FX); KEYTRUDA $4.8B (+23%), LAGEVRIO contributed $3.2B.
- GAAP EPS $1.70 vs $1.08; Non-GAAP EPS $2.14 vs $1.16, both well above prior year.
- Raises 2022 sales guidance to $56.9-$58.1B (17-19% growth); Non-GAAP EPS guidance $7.24-$7.36.
- JANUVIA/JANUMET sales fell 5% to $1.2B; expect loss of EU/China exclusivity in Q3 2022.
- Pipeline progress: FDA approvals for KEYTRUDA in MSI-H endometrial cancer and Lynparza in adjuvant breast cancer.